Principles of medication choice for treatment of chronic obstructive pulmonary disease according to new international guidelines
https://doi.org/10.18093/0869-0189-2013-0-2-89-94
Abstract
Principles of medication choice for treatment of chronic obstructive pulmonary disease according to new international guidelines.
About the Author
A. R. Tatarsky
ГБОУ ВПО "РНИМУ им. Н.И.Пирогова" Минздрава России
Russian Federation
Russian Federation
References
1. Глобальная инициатива по хронической обструктивной болезни легких. Пересмотр 2003 г. Пер. с англ. М.: Издательство "Атмосфера"; 2003.
2. Global initiative for chronic obstructive lung disease (GOLD); 2006. www.cgsmedicare.com
3. Global initiative for chronic obstructive lung disease (GOLD); 2011. www.cuidadosintensivos.net
4. Global initiative for chronic obstructive lung disease (GOLD); 2012. www.member.ghc.org
5. Agustí A., Celli B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterization. Eur. Respir. J. 2011; 38: 749–751. DOI: 10.1183/09031936.00062211.
6. Chetta A., Zanini A., Foresi A. et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am. J. Respir. Crit. Care Med. 2003; 167 (5): 751–757.
7. Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol. Int. 2010; 59 (1): 59–66.
8. Lundbäck B., Ronmark E., Lindberg A. et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir. Med. 2006; 100 (1): 2–10.
9. Woolcock A.J., Bastiampillai S.A., Marks G.B., Keena V.A. The burden of asthma in Australia. Med. J. Aust. 2001; 175 (3): 141–145.
10. Авдеев С.Н. Антибактериальная терапия при обострении хроничеческой обструктивной болезни легких. Пульмонология 2010; 2: 96–106.
11. Cazzola W., MacNee F.J. Martinez. Outcomes for COPD pharmacological trials: from lung functions to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469.
12. Mahler D.A. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2002; 110 (6, Suppl.): S298–S303.
13. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844.
14. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084–1091.
15. Vestbo J. New thinking and COPD. Ugeskr Laeger. 2003; 165 (45): 4319.
16. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. TORCH Study Group. Eur. Respir. J. 2004; 24 (2): 206–210.
17. Calverley P.M., Anderson J.A., Celli B. et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789.
Review
For citations:
Tatarsky A.R. Principles of medication choice for treatment of chronic obstructive pulmonary disease according to new international guidelines. PULMONOLOGIYA. 2013;(2):89-94. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-2-89-94
Views:
917
Email this article 